$10.49+0.00 (+0.00%)
Checkmate Pharmaceuticals Inc. (CMPI) is a Specialty Chemicals company listed on NASDAQ. There were no new wire items for CMPI in the last 30 days. The most recent was published Oct 30, 2024.
Latest news
25 items- PRAxonis Therapeutics Announces $115 Million Series A Financing-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- PRvenBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
- SECSEC Form 15-12B filed by Checkmate Pharmaceuticals Inc.15-12B - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
- 13D/GSEC Form SC 13G/A filed by Checkmate Pharmaceuticals Inc. (Amendment)SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
- 13D/GSEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
- 13D/GSEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
- 13D/GSEC Form SC 13D filed by Checkmate Pharmaceuticals Inc.SC 13D - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
- SECSEC Form EFFECT filed by Checkmate Pharmaceuticals Inc.EFFECT - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
- NEWSCompletion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers $2.5M Milestone Payment to XOMAKuros Biosciences AG ("Kuros" or the "Company"), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ:CMPI) by Regeneron Pharmaceuticals (NASDAQ:REGN). The completion triggers a $5 million milestone payment under a license agreement entered into by Kuros and Checkmate in 2015. Under a royalty purchase agreement entered into by Kuros and XOMA Corporation (NASDAQ:XOMA) in 2021, XOMA is entitled to receive 50% of the milestone payment paid to Kuros as a result of a change of control of Checkmate Pharmaceuticals. Therefore, $2.5 million of the $5 million milestone due to Kuros under the 2015 license agreement will be p
- SECSEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.25-NSE - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)
- INSIDERSEC Form 4 filed by Powell Michael4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Flaherty Keith T.4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Isacoff Oren4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Colabuono Peter4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Yan Joy4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Dolski Robert4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Wooldridge James4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Wigginton Jon Marc4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Fuhrman Alan4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- INSIDERSEC Form 4 filed by Bash Alan4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)
- SECSEC Form S-8 POS filed by Checkmate Pharmaceuticals Inc.S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
- SECSEC Form S-8 POS filed by Checkmate Pharmaceuticals Inc.S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
- SECSEC Form S-8 POS filed by Checkmate Pharmaceuticals Inc.S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
- SECSEC Form POS AM filed by Checkmate Pharmaceuticals Inc.POS AM - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
- SECCheckmate Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)
CMPI FAQ
8 questionsWhat does Checkmate Pharmaceuticals Inc. do?
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge...What is the latest news on CMPI?
Quantisnow has not tracked any new filings, ratings or press releases for CMPI in the last 30 days. The most recent wire item was published on October 30, 2024.Where does CMPI stock trade?
Checkmate Pharmaceuticals Inc. (CMPI) is listed on NASDAQ.What sector and industry is CMPI in?
Checkmate Pharmaceuticals Inc. operates in the Consumer Durables sector, Specialty Chemicals industry.When did Checkmate Pharmaceuticals Inc. go public?
Checkmate Pharmaceuticals Inc. (CMPI) completed its IPO in 2020.What are analysts saying about CMPI?
Across the last 1 analyst actions on Checkmate Pharmaceuticals Inc., there was 1 upgrade and 0 downgrades. The most recent action was from B of A Securities: Buy with a $7.00 price target on 2021-10-06. Recent price targets cluster around $7.00.What companies are similar to CMPI?
Notable peers in the same industry include CSL (Carlisle Companies Incorporated), CLX (Clorox Company), ASH (Ashland Inc.), HWKN (Hawkins Inc.), NPT (Texxon Holding Limited). Compare CMPI side-by-side with any of them on Quantisnow.How can I track CMPI on Quantisnow?
Quantisnow aggregates Checkmate Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMPI to receive live email and push alerts on every new disclosure.